Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
PFEPfizer(PFE) Benzinga·2024-08-01 02:56

On Tuesday, Pfizer Inc. PFE reported second-quarter adjusted EPS of 0.60,down110.60, down 11% year over year, beating the consensus of 0.46.The U.S. drugmaker reported sales of 13.28billion,up213.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of 13.02 billion.Truist Securities sees the strong demand growth as highly encouraging and, at current levels, Pfizer shares are very attractive given the company’s diverse portfolio that is gaining momentum, effective cost-cutting initiatives, and a commitment ...